B cell exchange across the blood-brain barrier in multiple sclerosis
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
In multiple sclerosis (MS) pathogenic B cells likely act on both sides of the blood-brain barrier (BBB). However, it is unclear whether antigen-experienced B cells are shared between the CNS and the peripheral blood (PB) compartments. We applied deep repertoire sequencing of IgG heavy chain variable region genes (IgG-VH) in paired cerebrospinal fluid and PB samples from patients with MS and other neurological diseases to identify related B cells that are common to both compartments. For the first time to our knowledge, we found that a restricted pool of clonally related B cells participated in robust bidirectional exchange across the BBB. Some clusters of related IgG-VH appeared to have undergone active diversification primarily in the CNS, while others have undergone active diversification in the periphery or in both compartments in parallel. B cells are strong candidates for autoimmune effector cells in MS, and these findings suggest that CNS-directed autoimmunity may be triggered and supported on both sides of the BBB. These data also provide a powerful approach to identify and monitor B cells in the PB that correspond to clonally amplified populations in the CNS in MS and other inflammatory states.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria
Polman, C. H., Reingold, S. C., Banwell, B., Clanet, M., Cohen, J. A., Filippi, M., Fujihara, K., Havrdova, E., Hutchinson, M., Kappos, L., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22366 · Cited by 9,802
B-cell depletion with rituximab in relapsing-remitting multiple sclerosis
Hauser, S. L., Waubant, E., Arnold, D. L., Vollmer, T., Antel, J., Fox, R. J., Bar-Or, A., Panzara, M., Sarkar, N., Agarwal, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706383 · Cited by 2,439
Self-citationSerafini, B., Rosicarelli, B., Magliozzi, R., Stigliano, E., & Aloisi, F. (2004) · Brain Pathology · doi:10.1111/j.1750-3639.2004.tb00049.x · Cited by 1,208
Cited by
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
Hauser, S. L., Bar-Or, A., Comi, G., Giovannoni, G., Hartung, H.-P., Hemmer, B., Lublin, F., Montalban, X., Rammohan, K. W., Selmaj, K., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1601277 · Cited by 2,021
Self-citationvon Büdingen, H.-C., Palanichamy, A., Lehmann-Horn, K., Michel, B. A., & Zamvil, S. S. (2015) · European Neurology · doi:10.1159/000377675 · Cited by 1,463
Self-citationClonally expanded B cells in multiple sclerosis bind EBV EBNA1 and GlialCAM
Lanz, T. V., Brewer, R. C., Ho, P. P., Moon, J.-S., Jude, K. M., Fernandez, D., Fernandes, R. A., Gomez, A. M., Nadj, G.-S., Bartley, C. M., et al. (2022) · Nature · doi:10.1038/s41586-022-04432-7 · Cited by 908
The promise and challenge of high-throughput sequencing of the antibody repertoire
Georgiou, G., Ippolito, G. C., Beausang, J., Busse, C. E., Wardemann, H., & Quake, S. R. (2014) · Nature Biotechnology · doi:10.1038/nbt.2782 · Cited by 652
Role of the innate and adaptive immune responses in the course of multiple sclerosis
Hemmer, B., Kerschensteiner, M., & Korn, T. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70305-9 · Cited by 584
B cells populating the multiple sclerosis brain mature in the draining cervical lymph nodes
Stern, J. N. H., Yaari, G., Vander Heiden, J. A., Church, G., Donahue, W. F., Hintzen, R. Q., Huttner, A. J., Laman, J. D., Nagra, R. M., Nylander, A., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008879 · Cited by 441
Integrated single cell analysis of blood and cerebrospinal fluid leukocytes in multiple sclerosis
Schafflick, D., Xu, C. A., Hartlehnert, M., Cole, M., Schulte-Mecklenbeck, A., Lautwein, T., Wolbert, J., Heming, M., Meuth, S. G., Kuhlmann, T., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-14118-w · Cited by 440
Reassessing B cell contributions in multiple sclerosis
Li, R., Patterson, K. R., & Bar-Or, A. (2018) · Nature Immunology · doi:10.1038/s41590-018-0135-x · Cited by 401
The immunology of multiple sclerosis
Attfield, K. E., Jensen, L. T., Kaufmann, M., Friese, M. A., & Fugger, L. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-022-00718-z · Cited by 380
Inflammasomes in neuroinflammation and changes in brain function: a focused review
Singhal, G., Jaehne, E. J., Corrigan, F., Toben, C., & Baune, B. T. (2014) · Frontiers in Neuroscience · doi:10.3389/fnins.2014.00315 · Cited by 365
Teriflunomide and Its Mechanism of Action in Multiple Sclerosis
Bar-Or, A., Pachner, A., Menguy-Vacheron, F., Kaplan, J., & Wiendl, H. (2014) · Drugs · doi:10.1007/s40265-014-0212-x · Cited by 356
B cells in autoimmune and neurodegenerative central nervous system diseases
Sabatino, J. J., Pröbstel, A.-K., & Zamvil, S. S. (2019) · Nature Reviews Neuroscience · doi:10.1038/s41583-019-0233-2 · Cited by 343
Innate Immunity in the CNS: Redefining the Relationship between the CNS and Its Environment
Lampron, A., ElAli, A., & Rivest, S. (2013) · Neuron · doi:10.1016/j.neuron.2013.04.005 · Cited by 284
Role of B Cells in Multiple Sclerosis and Related Disorders
Comi, G., Bar‐Or, A., Lassmann, H., Uccelli, A., Hartung, H., Montalban, X., Sørensen, P. S., Hohlfeld, R., Hauser, S. L., & Expert Panel of the 27th Annual Meeting of the European Charcot Foundation (2021) · Annals of Neurology · doi:10.1002/ana.25927 · Cited by 283
Self-citationB cells in multiple sclerosis — from targeted depletion to immune reconstitution therapies
Cencioni, M. T., Mattoscio, M., Magliozzi, R., Bar-Or, A., & Muraro, P. A. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-021-00498-5 · Cited by 271
Epstein–Barr Virus in Multiple Sclerosis: Theory and Emerging Immunotherapies
Bar-Or, A., Pender, M. P., Khanna, R., Steinman, L., Hartung, H.-P., Maniar, T., Croze, E., Aftab, B. T., Giovannoni, G., & Joshi, M. A. (2020) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2019.11.003 · Cited by 262
Cellular and molecular mechanisms of immunomodulation in the brain through environmental enrichment
Singhal, G., Jaehne, E. J., Corrigan, F., & Baune, B. T. (2014) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2014.00097 · Cited by 186
Clonal relationships of CSF B cells in treatment-naive multiple sclerosis patients
Eggers, E. L., Michel, B. A., Wu, H., Wang, S.-Z., Bevan, C. J., Abounasr, A., Pierson, N. S., Bischof, A., Kazer, M., Leitner, E., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.92724 · Cited by 93
“ally limited, suggesting selective recruitment and/or survival of B cell populations in the MS CNS (8, 10, 14).”
BackgroundSelf-citationEctopic Lymphoid Follicles in Multiple Sclerosis: Centers for Disease Control?
Negron, A., Stüve, O., & Forsthuber, T. G. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.607766 · Cited by 47
“produce proinflammatory cytokines that further contribute to inflammation and damage within the CNS (43, 78).”
BackgroundImmune-mediated processes in neurodegeneration: where do we stand?
Fakhoury, M. (2016) · Journal of Neurology · doi:10.1007/s00415-016-8052-0 · Cited by 43
Selective emergence of antibody-secreting cells in the multiple sclerosis brain
Bogers, L., Engelenburg, H. J., Janssen, M., Unger, P.-P. A., Melief, M.-J., Wierenga-Wolf, A. F., Hsiao, C.-C., Mason, M. R. J., Hamann, J., van Langelaar, J., et al. (2023) · eBioMedicine · doi:10.1016/j.ebiom.2023.104465 · Cited by 40
Protein kinase inhibitors as therapeutics in neurodegenerative and psychiatric disorders
Tridente, G., Jana, A., Nath, A., & Ashraf, G. M. (2023) · Receptor Tyrosine Kinases in Neurodegenerative and Psychiatric Disorders · doi:10.1016/b978-0-443-18677-6.00015-4 · Cited by 8
Metadata
- Authors
- von Büdingen, H.-C., Kuo, T. C., Sirota, M., van Belle, C. J., Apeltsin, L., Glanville, J., Cree, B. A., Gourraud, P.-A., Schwartzburg, A., Huerta, G., Telman, D., Sundar, P. D., Casey, T., Cox, D. R., & Hauser, S. L.
- Venue
- Journal of Clinical Investigation
- Published
- 2012-11-19
- Volume
- 122
- Issue
- 12
- Pages
- 4533-4543
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2126284284
- Cited by
- 239
- References
- 3
- FWCI
- 12.89
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.